Determination of Dialysis Dose A Clinical Comparison of Methods

Peter Ahrenholz¹, Petr Táborský², Margot Bohling³, Peter Rawer⁴, Noureddin Ibrahim⁵, Martin Gajdos⁶, Petr Machek⁷, Michaela Ságová⁸, Hans Gruber⁹, Pavel Moucka¹⁰, Ivan Rychlik¹¹, Gerd Leimenstoll¹², Gunter Tönne¹³, Jindriška Pössnickerová¹⁴, Jörg Woggan¹⁵, Werner Riegel¹⁶, Helmut Schneider¹⁷, Pavel Vyskocil^{†18}, Ralf Wojke¹⁹

Acknowledgements: Roland Winkler¹, Bernhard Fach⁴, Jiří Vlasák⁶, Katarina Nehézová¹¹, Jan Struck¹², Hans-Georg Wullstein¹⁵

¹ bioart products GmbH / Dialysis Center Rostock, Germany ² FME Dialysis Centre Prague 4, Czech Republic ³ PHV Dialysis Centre Wilhelmshaven, Germany ⁴ PHV Dialysis Centre Wetzlar, Germany ⁵ Dialysis Centre Döbeln, Germany ⁶ FME Dialysis Centre Sokolov, Czech Republic ⁷ FME Dialysis Centre Most, Czech Republic ⁸ FME Dialysis Centre Prague Motol, Czech Republic ⁹ Dialysis Centre Landshut, Germany ¹⁰ FME Dialysis Centre Kolin, Czech Republic ¹¹ FME Dialysis Centre Prague Vinohrady, Czech Republic ¹² PHV Dialysis Centre Kiel, Germany ¹³ Dialysis Centre Warendorf, Germany ¹⁴ FME Dialysis Centre Chomutov, Czech Republic ¹⁵ Dialysis Centre Hamburg Poppenbüttel, Germany ¹⁶ Medical Clinic III, Klinikum Darmstadt, Germany ¹⁷ PHV Dialysis Centre Harsewinkel, Germany ¹⁸ FME Dialysis Centre Louny, Czech Republic ¹⁹ Clinical Reseach FME, Bad Homburg, Germany PHV = Patienten-Heimversorgung FME = Fresenius Medical Care

Introduction and Objectives

Within the dialysis community quality standards have been debated extensively; the European Best Practice Guidelines recommended as minimum treatment dose an equilibrated Kt/V = 1.2¹. In clinical practice this minimum threshold value is not achieved for each and every patient. 2,3

Clinical practice guidelines such as NKF-K/DOQI or European Best Practice Guidelines recommend regular measurements of the delivered haemodialysis dose Kt/V using a validated method. Nowadays, automatic on-line measurements are available, as alternatives to the conventional method with blood samples, adjacent laboratory analysis of urea concentrations and subsequent calculation.

Methods

The clinical trial was designed as prospective, observational, international, multi-centre study to compare three different methods of dialysis dose assessment in clinical routine: Kt/VDau, Kt/Vocм, and Kt/Vвсм.

The dialysis dose measured via blood samples, laboratory analysis of the urea concentration and application of Daugirdas' formula is evaluated in this study as standard method (*Kt/V*Dau).

The dialysis dose measured via automatic \underline{O} n-line \underline{C} learance \underline{M} onitor (OCM) with anthropometric estimate (Watson) of the urea distribution volume \boldsymbol{V} is the second method determined in this study (Kt/Vocm).

For a more accurate *Kt/V* measured by OCM the urea distribution volume *V* is additionally measured by the Body Composition Monitor (BCM, Fresenius Medical Care) instead of being only estimated: This is the third method to determine dialysis dose (Kt/VBCM).

In this study these 3 different methods to determine dialysis dose were simultaneously applied in each patient. The trial was planned as a study with all eligible patients of each study centre, thus a nearly complete cross-section of those patients, who comply with the selection criteria.

Results

18 European dialysis centres participated in this prospective clinical trial. 1606 patients on haemodialysis (HD) or on-line-HDF (oHDF) were screened whether eligible for the study, 1089 patients were enrolled, and 1076 patients had full data set and were analyzed, see Fig. 1.



In the analysis cohort 38 % of the patients were treated by HD and 62 % by oHDF, for patient characteristics see Table 1: The mean values for oHDF in comparison to HD show lower age (-5.4 years), more males (+3.5 %), slightly higher BMI (+0.1 kg/m²) and more anuric

patients (+15 %).	Characteristics	Units	All Patients (N=1076)	Patients on HD (N=407)	Patients on oHDF (N=669)	
Table 1	Age	years	66.0 ± 13.9	69.3 ± 13.2	63.9 ± 13.9	
Patient characteristics of the analysis cohort (N=1076); data expressed as	Sex	%: male female	57.0 / 43.0	54.5 / 45.5	58.4 / 41.6	
number, mean value ± standard devia- tion or percentage.	Body mass index	kg/m²	26.1 ± 5.2	26.0 ± 5.1	26.1 ± 5.2	
	Residual renal function*	low %: medium high	30 / 25 / 45	21 / 22 / 57	36 / 26 / 38	

For treatment data see Table 2: The mean values for oHDF in comparison to HD show

Fig. 2 Box and whisker plot of dialysis dose in the analysis

population (1076 patients): Dialysis dose measured by <u>O</u>n-line <u>C</u>learance <u>M</u>onitor with estimated urea distribution volume <u>Watson</u> (*Kt/Vocm*), dialysis dose determined by on-line clearance monitor with measured urea distribution volume VBCM (Kt/VBCM), .and conventional dialysis dose with blood samples, urea concentration determination and Daugirdas' formula (Kt/VDau).



In the analysis cohort dialysis dose was measured as Kt/Vocm=1.47±0.34, Kt/VBcm=1.65 ±0.42, and Kt/VDau=1.74±0.45, see Fig. 2. On average, Kt/Vocm resulted in 16 % lower values compared to Kt/VDau, whereas Kt/VBCM was 5 % lower than Kt/VDau. Outliers were incidentally observed for Kt/VDau due to falsely high urea reduction ratio >95% (possible measurement or laboratory errors), whereas OCM based dose measurements Kt/Vocm and Kt/VBCM delivered realistic values. Correlation between Kt/VDau (without outliers) and Kt/VOCM was 0.81, and 0.82 between Kt/VDau (without outliers) and Kt/VBCM, see also Fig. 3.

Fig. 3

Dialysis dose in the analysis population (1076 patients): Dialysis dose determined by on-line monitor with measured urea distribution clearance volume V (Kt/VBCM) compared to the conventional dialysis dose with blood samples, urea concentration determination and Daugirdas' formula (Kt/VDau).



Comparison between Kt/VDau and Kt/VBCM shows acceptable agreement over the whole range, independent of Kt/V, see Fig. 4.



Discussion

Methods to quantify dialysis dose based on blood sampling are critical concerning proper timing, compliance with recommended methods, and are known for occasional mistakes in handling, storage or transport of the samples or in laboratory errors of measuring urea.⁵⁻¹⁰ The second generation Daugirdas' formula was modelled in 1993 from 500 HD sessions with a total error in an acceptable 5% range throughout the investigated range of dialysis doses (0.7 < Kt/V < 2.1).⁵ We observed that the conventional method Kt/V bau based on blood sampling was occasionally prone to outliers, whereas the automated dialysis dose determinations Kt/Vocm and Kt/VBcm delivered plausible values.

Although the On-line Clearance Monitor accurately measures urea clearance K and effective dialysis duration t^{11} , for the dialysis dose Kt/V an accurate urea distribution volume V is mandatory. The anthropometric Watson formula was derived from 723 adults obtained from dilution studies,¹² it is applied as default value in the dialysis monitor 4008 and 5008. Meanwhile, this anthropometric estimate was suggested to overestimate the total body water of HD patients. 4,13-17

longer treatment duration (+26 min), more processed blood (+15 L), slightly higher pre- and post-dialytic body weight (+1.6 kg and +1.2 kg) and higher ultrafiltration volume (+0.6 L).

Table 2

Treatment data of the analysis cohort (N=1076); data expressed as mean value ± standard deviation.

Treatment data			Patients on HD (N=407)	Patients on oHDF (N=669)	
Dialysis duration	h	4.35 ± 0.47	4.18 ± 0.46	4.44 ± 0.45	
Pre-dialytic weight	kg	76.5 ± 16.9	75.5 ± 16.6	77.1 ± 17.1	
Post-dialytic weight	kg	74.6 ± 16.6	73.9 ± 16.3	75.1 ± 16.8	
Ultrafiltration volume	L	2.34 ± 1.21	1.97 ± 1.19	2.57 ± 1.17	
Volume of pro- cessed blood	L	82.7 ± 19.3	73.4 ± 18.4	88.4 ± 17.5	

*low: < 100 ml/day, 100 ml/day ≤ medium ≤ 500 ml/day, high: > 500 ml/day

As already observed by others⁴ the mean urea distribution volume was larger if anthropometrically estimated than if measured (-1.7 L), see Table 3. The mean dialysis doses were higher for oHDF in comparison to HD, independently from the determination method (*Kt/V*Dau: +0.36, *Kt/V*OCM: +0.28, *Kt/V*BCM: +0.33).

iis ort an	Dialysis dose data	Units	All Patients (N=1076)	Patients on HD (N=407)	Patients on oHDF (N=669)	
	V _{Watson}	L	37.5 ± 7.0	36.8 ± 7.0	37.9 ± 7.1	
	V _{BCM}	L	35.8 ± 7.5	35.3 ± 7.3	36.0 ± 7.6	
	Kt/V _{Dau}	-	1.74 ± 0.45	1.51 ± 0.40	1.87 ± 0.43	
	Кt/V _{осм}	-	1.47 ± 0.34	1.30 ± 0.30	1.58 ± 0.32	
	Kt/V _{BCM}	-	1.65 ± 0.42	1.44 ± 0.37	1.77 ± 0.40	

Table 3

Urea distribution volume V and dialysis dose Kt/V in the analysis cohor (N=1076); data expressed as mear value ± standard deviation. The accuracy of BCM to determine total body water was evaluated earlier in more than 1,000 healthy individuals against available gold standard reference methods (e.g. bromide, deuterium, dual-energy X-ray absorptiometry, air displacement plethysmography, clinical assessment), and agreement with clinical assessment of fluid status was demonstrated in several hundred patients.^{18,19} In our study the BCM measurement delivered with 35.8 L a mean urea distribution volume V that was 1.7 L lower than the estimate derived from the Watson formula. Due to this lower urea distribution volume the dialysis dose Kt/VBCM (with all parameters K, t, and V measured) was higher than the dialysis dose Kt/VocM (with only K and t measured, and V estimated according to Watson) and closer to Kt/VDau.

Conclusions

Due to the automated procedure the on-line clearance measurement with the Watson estimate of the urea distribution volume *Kt/Vocm* was easiest to use, but the difference to the conventional method was larger; the automatic on-line clearance measurement with the urea distribution volume measured by Body Composition Monitor Kt/VBCM had a higher correlation to the conventional method.

REFERENCES EFENCES Europain Best Practice Guidelines for Haemodialysis (part 1). Nephrol Dial Transplant2002; 17 (suppl 7): S18-31. Coyne D. Defmez J. Spence G. et al. Impaired delivery of hemodialysis prescriptions: an analysis of causes and an approach to evaluation. J Am Soc Nephrol. 1997 Aug.8(2):1315-8. Press M. Benz R. Z. Journifying the red crutosis that imma for WODD Luce actudurin and subject on 2046 point. Clin Nephrol. 2006 Aug.8(2):1316-8. Nepers M. Benz R. Z. Journifying the red crutosis that imma for WODD Luce actudurin and subject on 2046 point. But Press M. Benz R. Z. Neperbergue J. But Press M. Benz R. Z. Neperbergue J. But Press M. Benz R. J. Benz R. S. Neperbergue J. But Press M. Benz R. Z. Neperbergue J. But Press M. Benz R. J. But Press M. Benz R. J. But Press M. Benz R. Z. Neperbergue J. But Press M. Benz R. Z. Neperbergue J. But Press M. Benz R. J. Benz R. Be (kbppenbry W, Skpeman C, el Jong P, et al. Anthropometry-based equations overestmate the una distribution volume in hieroinsep parene. Name you have not many yours or building of the start of the s